** Drug developer Disc Medicine's IRON.O shares fall ~5% to $59.46
** Company says in filing it expects to report material weakness in its internal control over financial reporting for year ending Dec. 31, 2024
** Disc Medicine adds issue due to ineffective Information Technology General Controls (ITGC) - policies aimed at keeping the company's IT systems secure and working properly - over some key financial IT systems
** Company says no misstatements have been identified in its financial statements so far
** Disc Medicine says its auditor has not completed the audit of its internal controls and cannot provide an opinion yet
** All 11 brokerages rate the stock "buy" or higher; median PT $90 - LSEG
** Company's shares gained 6.1% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。